Omeros (NASDAQ:OMER - Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.04, Zacks reports.
Omeros Price Performance
Shares of OMER stock traded down $0.81 on Monday, hitting $16.68. The stock had a trading volume of 1,506,323 shares, compared to its average volume of 1,596,064. The firm has a market capitalization of $1.21 billion, a P/E ratio of 13.03 and a beta of 2.96. Omeros has a 1 year low of $6.70 and a 1 year high of $21.24. The company's 50 day moving average price is $18.27 and its 200-day moving average price is $13.74.
Insider Transactions at Omeros
In related news, VP Peter B. Cancelmo sold 25,000 shares of Omeros stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This trade represents a 99.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO David J. Borges sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total transaction of $209,500.00. Following the sale, the chief accounting officer owned 5,000 shares in the company, valued at $104,750. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 100,906 shares of company stock valued at $1,904,955. Insiders own 10.50% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. HC Wainwright reissued a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $22.00 price target on shares of Omeros in a research note on Wednesday, October 14th. Wall Street Zen upgraded Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Omeros from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.
View Our Latest Stock Report on OMER
Omeros Company Profile
(
Get Free Report)
Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.